Floatz logo

EF-5

Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)

National Cancer Institute (NCI)Small moleculePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2B
Irinotecan
National Cancer Institute (NCI)
Phase 1CCC
Vorinostat
National Cancer Institute (NCI)
Phase 1CCC
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 1CCC

View all 30 →

Same molecule, other indications

EF-5 is also rated in:

cervical cancerDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
Stage I Ovarian Epithelial CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →